Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 59%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Natera is well positioned in the market due to their innovative technologies and strong track record, with recent approval in Japan for their MRD test and plans for global expansion. Success in their women's health and organ transplant businesses, along with a 10% increase in stock, demonstrate their potential for growth. However, external factors such as reimbursement changes and market saturation could affect their growth trajectory moving forward.

Bears say

Natera is facing a few challenges ahead. First, although Natera has been eyeing Japan as a potential growth market, the company has yet to see meaningful revenue contribution from this region, potentially indicating difficulties in penetrating this market. Second, while Natera has had success in securing Medicare coverage for its products, there may be uncertainty and potential delays in securing similar coverage from commercial payors. Lastly, while the company has seen consistent growth in Signatera's average selling price, there is a risk that this growth could stall as a result of limited opportunities for further adoption in established use cases.

Natera (NTRA) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 59% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 17 analysts, Natera (NTRA) has a Buy consensus rating as of Aug 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $273.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $273.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.